Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator-Reference-Cited by-同舟云学术

Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator

Published:2007-04 Issue:4 Volume:1 Page:387-399
ISSN:1862-8346
Container-title:PROTEOMICS – Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

Jüllig Mia,Chen Xiuyin,Hickey Anthony J.,Crossman David J.,Xu Aimin,Wang Yu,Greenwood David R.,Choong Yee Soon,Schönberger Sarah J.,Middleditch Martin J.,Phillips Anthony R. J.,Cooper Garth J. S.

Publisher

Wiley

Subject

Clinical Biochemistry

Reference87 articles.

1. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment

2. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths

3. Regeneration of the Heart in Diabetes by Selective Copper Chelation

4. Demonstration of a Hyperglycemia-Driven Pathogenic Abnormality of Copper Homeostasis in Diabetes and Its Reversibility by Selective Chelation

5. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shedding Novel Photophysical Insights Toward Discriminative Detection of Three Toxic Heavy Metal Ions and a hazard class 1 nitro-explosive By Using a Simple AIEE Active Luminogen;Journal of Fluorescence;2023-08-05

2. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy;Heart;2023-05-03

3. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies;Cell Death & Disease;2023-02-11

4. Role of Trientine in Hypertrophic Cardiomyopathy: A Review of Mechanistic Aspects;Pharmaceuticals;2022-09-14

5. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline;Expert Opinion on Investigational Drugs;2022-09-13